Merck has acquired IOmet, a UK-based drug discovery company focused on cancer immunotherapy and cancer metabolism, gaining its preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors. IOmet will become a wholly owned subsidiary of Merck. Financial terms were not disclosed. “By harnessing the power of the immune system, we are already witnessing great advancements in the treatment of cancer,” said Eric Rubin, M.D., vice ...